High-Dose vs. Standard-Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU-1.

ABSTRACT: Patients with hypertension (HTN) face an increased risk of complications and mortality from influenza; a risk that may be modified by influenza vaccination. There is limited evidence on the effectiveness of high-dose (HD-IIV) compared with standard-dose (SD-IIV) inactivated influenza vaccines in hypertensive individuals. This study, a post hoc analysis of DANFLU-1, a pragmatic, and open-label, individually randomized trial of HD-IIV vs. SD-IIV conducted during the 2021-2022 influenza season among participants aged 65-79 years. Prespecified outcomes in DANFLU-1 included hospitalization for influenza or pneumonia, cardiovascular, cardiorespiratory, and respiratory hospitalizations, all-cause hospitalization, and all-cause mortality. Outcomes were analyzed as both time-to-first and recurrent

SUBMITTER: Langhoff AF 

PROVIDER: S-EPMC12618134 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature